XML 114 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2013
United Therapeutics Corporation [Member]
Licensing Agreements [Member]
Jun. 30, 2013
United Therapeutics Corporation [Member]
Licensing Agreements [Member]
Jun. 30, 2012
United Therapeutics Corporation [Member]
Licensing Agreements [Member]
Jun. 30, 2013
Restricted Shares and Restricted Share Units [Member]
Jun. 30, 2012
Restricted Shares and Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Granted, weighted-average grant date fair value             $ 3.43 $ 2.54
Grants received $ 10,882 $ 9,412            
Severance expenses 329 275 225          
Derivative fair value asset (liability) 93 (138)            
Revenue [Line Items]                
Contingent consideration receivable if certain regulatory milestones are reached         37,500      
Deferred revenue from the license agreement with united therapeutics         5,000      
Deferred revenue recognition period for the upfront license fee from united therapeutics         11 years 6 months 6 years 6 months    
Remaining revenue recognition period         9 years 6 months      
Revenues 679 716    195 779      
Future revenues after change in estimate       95 379      
Advance payment for development costs         2,000      
Research and development expenses 19,906 12,685 8,311   1,607      
Reclass from R&D expense to cost of revenue   $ 21